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Abstract
Background: Yunnan province in China has a high tuberculosis (TB) burden. Cure rates in general are high, but
they were below the target of 85% in 26 out of 129 counties in 2005. In these 26 counties we assessed which
patient-related and treatment-related factors were associated with non-cure.
Methods: We conducted a prospective cohort study. Smear positive pulmonary TB patients treated at the local
Center for Disease Control and Prevention (CDC) were interviewed before start of treatment and during the fifth
month of treatment using structured questionnaires. Information on treatment outcome was extracted from
patient records. Patients cured at the end of treatment were compared to patients with unsuccessful treatment
outcomes (failure, default, and death).
Results: A total of 841 patients were registered between January-June 2007 of which 792 (94%) were cured.
Independent risk factors for non-cure were having a low income (<3000 RMB per year), not having medical
insurance, a delay in health care seeking >30 days, a positive smear test result two months after start of treatment,
not being aware of the need to go to the CDC for medical follow up during treatment, and not seeing the need
for treatment observation.
Conclusion: Reducing the financial burden of TB disease and providing health education to improve compliance
with treatment could increase the proportion of patients with successful treatment outcomes.
Background
High quality tuberculosis (TB) treatment is a key factor
of the Directly Observed Treatment Short-course
(DOTS) strategy. In combination with a high case detec-
tion rate it is expected to reverse the TB epidemic. The
targets for case detection and treatment success are 70%
and 85% respectively [1]. Treatment success is defined
as bacteriologically confirmed cure or a completed
course of treatment without bacteriological proof of
cure [2]. TB patients with an unsuccessful treatment
outcome, especially failure and default, are a public
health concern as these patients may have developed
drug resistance and remain infectious for prolonged per-
iods of time.
TB treatment outcomes are influenced by bacterium
characteristics such as drug resistance, patient character-
istics, patient behavior, and quality of health care [3-8].
Poor adherence to anti-tuberculosis treatment is consid-
ered the most important factor leading to non-curein
patients infected with strains susceptible to the drugs
[9-11]. Therefore, observation of treatment is considered
o n eo ft h ek e ye l e m e n t so ft h eD O T Ss t r a t e g y .I th a s
been described before that in some places directly
observed treatment (DOT) by village health workers was
not very successful, due to insufficient financial incen-
tives for the village health workers in relation to the
task of thrice-weekly DOT for 6-8 months [12]. In
remote areas, DOT can also be performed by an
educated family member or community volunteer [2].
The influence of this approach on treatment outcomes
is not known.
Yunnan province in southern China is a high TB bur-
den province with poor economic status. The province
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2 of which 94% is mountainous area.
Seventy-four percent of the 44 million inhabitants live
in rural areas. Under China’s National TB Control Pro-
gram (NTP), Yunnan province has implemented the
DOTS strategy since 2002. In 2004, based on estimates
by the Ministry of Health, the provincial case detection
rate reached 70% [13]. In 2005, the average treatment
success rate was 92% and the average cure rate was
92%. In 24 out of the 129 counties in Yunnan the treat-
ment success rate was below 85% and in 26 counties the
cure rate was below 85%.
The Center for Disease Control and Prevention (CDC)
of Yunnan province decided to assess which TB patient-
related and treatment-related factors are the main deter-
minants for non-cure in the counties of Yunnan pro-
vince in China with a relatively low cure rate. Therefore,
we conducted a prospective cohort study in counties
with a cure rate below 85% in 2005. The results may be
used to develop policies to improve treatment success in
those areas.
Methods
Setting, study design, and population
A prospective cohort study was performed in these
counties to identify factors that are associated with non-
cure. All new sputum smear-positive TB patients over
14 years of age registered between January and June
2007 by the local CDC in the 26 counties with a cure
rate <85% in 2005 were eligible for inclusion in our pro-
spective cohort study. Informed consent was taken
before inclusion in the study.
Sample size
For the sample size calculation we considered type of
treatment observer as the main factor associated with
treatment outcome. We assumed that 67% of the TB
patients are observed by a family member and the
remaining 33% are observed by a village doctor (ratio
2:1, based on expert opinion). We wanted to be able to
show a difference in treatment success rate of 10%
between the two groups (85% in those observed by a
family member and 95% in those observed by a village
doctor). Taking into account a maximum of 15% miss-
ing data, a power of 0.8 and alpha of 0.05, a total sample
size of 744 patients was required.
Data collection
All eligible TB patients were approached by the local
CDC doctors. TB patients who agreed to participate in
the survey were interviewed before start of TB treatment
and during the fifth month of treatment using struc-
tured questionnaires. In the first interview we collected
information about patient characteristics, such as
age, sex, educational background, TB symptoms, and
co-morbidity (diabetes, HIV/AIDS, lung cancer, liver
and kidney diseases, and other co-morbidity). Informa-
tion on treatment adherence, side effects, patient’s
knowledge of TB treatment and perceived need for
DOT was included in the second interview. At that
time, treatment observers were also interviewed to col-
lect information on direct observation of treatment and
treatment interruption.
All TB patients were registered, treated and managed
according to the procedures of the National Tuberculo-
sis Control Plan. They all started standardized treatment
directly after registration. The standardized treatment
regimen consists of two months of thrice-weekly isoni-
zid, rifampicin, pyrazinamide and ethambutol followed
by four months of thrice-weekly isoniazid and rifampi-
cin. Patient supervision and follow-up with sputum
smear tests during and at the end of treatment was con-
ducted as per the NTP guidelines.
Information on chest radiograph results and sputum
smear microscopy results at month 2-3, month 5 and
month 6 was extracted from the TB patient medical
record at the local CDC. Treatment outcomes were
registered at the end of treatment according to the
WHO definitions [2].
Questionnaires were pre-tested, and modified accord-
ing to the lessons learned in the pre-test. Directly after
the interview the filled in questionnaires were checked
for completeness and consistency. The researchers re-
interviewed a random sample of 10% of the included
individuals and cross checked data with other data
sources. Rechecking showed satisfactory data quality.
Operational definitions
We used the definitions of the WHO for new smear-
positive TB patient and treatment outcome [2]. Success-
ful treatment includes cure and treatment completion,
and unsuccessful treatment includes failure, death, and
default. We also used the WHO definition for reporting
of smear microscopy, where the reported result indicates
the number of acid-fast bacilli observed. A result of at
least 2 relates to at least 1 acid-fast bacillus observed
per microscopy field [14].
Annual income was categorized into three groups of
equal size: low income group <3000 Yuan (RMB); med-
ium income group 3000-7000 Yuan (RMB); and high
income group >7000 Yuan (RMB). One Yuan equalled
about 0.13 USD in 2007.
According to China’s TB Control Program (NTP)
guidelines, anti-TB drugs should be taken every other
morning (on even dates) before breakfast. Patients tak-
ing drugs at other times or intervals were considered as
taking drugs not according to the guidelines.
Interruption of treatment mea n st h a tp a t i e n t sm i s s e d
at least one dose during treatment. Interruption of
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drugs during intensive phase, or (2) interruption of tak-
ing drugs during continuation phase, or (3) interruption
of taking drugs during both phases.
Data management and analysis
Individual patient data were double entered by different
persons in Epi data version 3.0 (Epidata Association,
Denmark, 2006), and differences were checked. Patient
data were analyzed using R software version 2.7.1
(R, New Zealand, 2008). A simple descriptive analysis
was performed using percentages, means, medians, and
standard deviations (SD). For the univariate analyses c
2
tests or Fisher’s exact tests were used to compare the
distribution of categorical variables between groups. The
t-test was used to compare the distribution of age
between participants and non-participants registered
and treated by the TB dispensaries at the local CDCs.
Logistic regression analysis was conducted to identify
risk factors for non-cure. Variables yielding a P-value
≤ 0.2 in the univariate analysis were included in the mul-
tivariate analysis, and the model was refined by backward
elimination guided by the change in log likelihood of
successive models with a significance level of 0.05.
Ethical considerations
The principles of the Helsinki Declaration were taken
into account. Written, informed consent was obtained
from all study subjects. The study was approved by the
medical ethical committee of the Chinese TB Control
Association.
Results
Of the 905 eligible TB patients registered between Janu-
ary and June 2007 in the 26 study counties, 59 (6.5%)
refused to participate, leaving 846 patients. Of the 846
patients interviewed before start of treatment, 833 were
also interviewed during the fifth month of treatment.
Eight could not be interviewed again as they had died,
and five had defaulted and could not be traced. Of the
TB patients who refused to participate, 35 (59.3%) were
male versus 576 (68.1%) of the participating TB patients
(p = 0.28). Non participating patients were slightly older
than participating patients (median age (SD), 39 (15.3)
vs. 37 (15.7), p = 0.11). Of the patients that refused to
participate, 9 (15.0%) had an unsuccessful treatment
outcome.
The treatment success rate for the included smear
positive pulmonary patients was 94%; 792 (93.6%) were
cured and 5 (0.6%) completed treatment. Out of the 49
patients with unsuccessful treatment outcome, 17 (2.0%)
failed treatment, 13 (1.5%) stopped prematurely due
to side effects, 10 (1.2%) defaulted, and 9 (1.1%)
patients died. Those who completed treatment without
bacteriological confirmation of cure were deleted from
the analyses as it was not clear whether they were actu-
ally cured, leaving 841 patients for the study. Including
these 5 patients in the group with successful treatment
outcome did not affect the results significantly (data not
shown).
Table 1 shows the characteristics of the participants.
Most patients were male (68.4%), under 30 years of age
(33.9.%), had no formal education beyond primary
school (62.6%), and had medical insurance (81.8%).
Seventhy-one percent of patients delayed seeking health
care for TB symptoms for more than 30 days,. Almost
all (98.0%) had a sputum smear examination result after
two months of treatment, and 11.7% of those were still
sputum smear positive. Treatment was not observed for
27.7% of patients while for 49.3% of patients, treatment
was observed by family members only. In 10.1% of
cases, treatment was partly observed by health workers
and partly by family members. Almost one in five
patients (18.4%) indicated to have interrupted treatment.
During the fifth month of treatment, 9.0% of patients
were unaware that during the treatment period he/she
should go the CDC three times for medical follow-up
including sputum smear examination; 38.4% did not
know the correct treatment duration, and 74.7% did not
perceive direct observation of treatment as necessary. A
large proportion of those who reported to be unaware
of the need for follow-up had interrupted treatment
(87% versus 22%, p < 0.001). Within this subgroup that
had interrupted treatment and reported to be unaware
of the need for follow-up, 52% had missed up to seven
doses in a row and 48% had missed more than seven
doses consecutively.
In univariate analysis, patient characteristics signifi-
cantly associated with non-cure were having no medical
insurance, patient delay in seeking care for TB symp-
toms >30 days, and high initial sputum acid fast bacilli
load (>2+) (Table 1). Treatment-related characteristics
significantly associated with non-cure in univariate ana-
lysis were still having a positive sputum smear after two
months of treatment, not having a DOT supervisor, and
not taking drugs according to the NTP guideline. Also,
patients who indicated that observation of treatment
was not necessary, patients who were unaware of the
need to go at least three times to the local CDC during
treatment, and patients being unaware of the correct
treatment duration were at increased risk of non-cure
outcome.
Patient and treatment characteristics independently
associated with non-cure were having no medical insur-
ance, a low income, patient delay >30 days, a positive
2-month smear test result, being unaware of the need
to go to local CDC for check-ups during treatment,
and refusal of direct observation of taking drugs.
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Page 3 of 7Table 1 Patient and treatment characteristics associated with non-cure in Yunnan province, China (N = 841)
Characteristic N(%) non-cure (%) RR 95% CI p-value
Sex 0.27
Male 575 (68.4) 37 (6.4) 1
Female 266 (31.6) 12 (4.5) 0.69 0.35 - 1.3
Age (years) 0.66
<30 285 (33.9) 18 (6.3) 1
≥30 556 (66.1) 31 (5.6) 0.88 0.48 - 1.6
Education level** 0.01
No formal education or primary school only 520 (62.6) 38 (7.3) 1
Secondary school or higher 311 (37.4) 10 (3.2) 0.42 0.21 - 0.86
Medical insurance 0.02
No 153 (18.2) 15 (9.8) 1
Yes 688 (81.8) 34 (4.9) 0.48 0.32 - 0.90
Income*,** 0.11
Low 314 (37.3) 21 (6.7) 1
Middle 239 (28.4) 18 (7.5) 1.1 0.59 - 2.2
High 288 (34.3) 10 (3.5) 0.50 0.23 - 1.12
Co-morbidity 0.06
No 755 (89.8) 40 (5.3) 1
Yes 86 (10.2) 9 (11.6) 2.1 0.98 - 4.5
Patient delay (days) 0.02
<30 243 (28.9) 7 (2.9) 1
≥30 598 (71.1) 42 (7.5) 2.5 1.1 - 5.8
Directly observed treatment 0.01
Yes, by health care staff 108 (12.8) 4 (3.7) 1
Yes, shared by health care staff and family member 85 (10.1) 9 (10.6) 3.1 0.9 - 10.4
Yes, by family member 415 (49.3) 15 (1.8) 0.98 0.32 - 3.0
No 233 (27.7) 21 (9.0) 2.6 0.86 - 7.7
Sputum smear status before treatment 0.03
≤2+ 503 (59.8) 22 (4.4) 1
>2+ 338 (40.2) 27 (8.0) 1.9 1.1 - 3.4
Sputum smear result after 2 months of treatment 0.01
Negative 726 (86.3) 21 (2.9) 1
Positive 98 (11.7) 11 (11.1) 4.2 2.0 - 9.1
Without test 17 (2.0) 17 (100) 34.8 24.7 - 48.6#
Adverse events** 0.06
No 539 (65.8) 22 (4.1) 1
Yes, did not require hospitalization 262 (32.0) 10 (3.8) 0.93 0.44 - 2.0
Yes, required hospitalization 18 (2.2) 3 (16.7) 4.7 1.3 - 17.4
Interruption of treatment 0.17
No 686 (81.6) 39 (5.7) 1
Yes, during intensive phase 28 (3.3) 3 (10.7) 2.0 0.58 - 6.9
Yes, during continued phase 96 (11.4) 3 (3.1) 0.54 0.16 - 1.8
Yes, during intensive and continuation phase 31 (3.7) 4 (12.9) 2.5 0.82 - 7.4
Maximum number of missed doses in a row** 0.09
0 682 (81.6) 35 (5.1) 1
1-7 102(12.2) 3 (2.9) 0.56 0.17 - 1.9
>7 52 (6.2) 6 (11.5) 2.4 0.97 - 6.0
Taking drugs according to guideline < 0.001
Yes 638 (75.9) 19 (3.0) 1
No 203 (24.1) 30 (14.8) 5.7 3.1 - 10.3
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less than two weeks less often were cured than patients
who reported never to have missed a dose (Table 2).
Discussion
Many factors were observed to be related to non-cure in
this study. Independent risk factors for non-cure of new
smear-positive TB patients in the selected counties with
a low cure rate in Yunnan province were: having no
medical insurance; a low income, patient delay >30 days;
a positive 2-month smear test result; being unaware of
the need to go to local CDC for check-ups during treat-
ment; and refusal of direct observation of drugs taking.
Almost one in ten patients (9.0%) were unaware of the
need to go to local CDC for medical check-ups includ-
ing sputum smear examinations. These patients had an
eight times higher risk of non-cure than patients who
knew that they should attend medical check-ups at the
CDC. More than one in ten patients (11.7%) still had a
positive sputum smear after two months of treatment,
which is lower than the 18% observed in the registration
data of Yunnan province in 2007 (unpublished data).
Patients who were still sputum smear positive after two
months had a six to seven times increased risk of non-
cure. Other independent risk factors for non-cure were
not having medical insurance, a low income, patient
delay in health care seeking for TB symptoms >30 days,
not taking drugs according to the guideline, and not
seeing the need for observation of treatment. Patients
who indicated that they never had missed a dose more
often were not cured than patients who indicated to
have missed a maximum of 1-7 doses in a row. This is
in contradiction with results of previous studies
[4,15-17]. In these studies treatment interruption was
associated with an increased risk of non-cure. The con-
tradiction may partly be explained by the fact that many
p a t i e n t sw h od i e do rf a i l e dt r e a t m e n th a dn o tm i s s e d
any dose according to the information provided: 92%
versus 95% among those cured. Furthermore, it may be
that some patients that reported not to have missed a
single dose might be afraid to admit that in fact they
had missed some doses. Especially patients that did not
r e s p o n dw e l lt ot r e a t m e n tm a yb el e s sl i k e l yt oa d m i t
that they missed doses.
Patients with positive smears after 2 months of treat-
ment may not react well to treatment due to an infection
with drug resistant Mycobacterium tuberculosis,o n eo f
the major risk factors for non-cure. Drug susceptibility
testing and treatment for multi-drug resistant tuberculo-
sis were not implemented within the NTP in Yunnan
province during the study, and no drug resistance survey
has been conducted. We were unable to obtain informa-
tion about the presence of drug resistance [18].
Patients with a DOT observer had a decreased risk of
non-cure compared to patients without a DOT observer
in univariate analysis, as has been observed in other stu-
dies [19-21]. Half of the patients had a family member
as DOT observer and their outcomes were similar to
the patients who had a health care worker as DOT
observer. A recent study from Tanzania also observed
similar treatment outcomes for sputum smear positive
TB patients with community members, mostly family
members, being DOT supervisors, compared to those
with facility-based DOT [22].
Treatment was not observed at all for 28% of patients.
DOT is the cornerstone of the DOTS strategy in China.
In our data, lack of treatment observation was not an
independent risk factor when adjusting for other factors
influencing treatment outcome. This could be due to
the fact that quality of DOT is not always sufficient,
even if performed by health care workers like village
doctors [12,23]. If it is not possible to increase the
Table 1 Patient and treatment characteristics associated with non-cure in Yunnan province, China (N = 841)
(Continued)
Patient knows that during treatment he/she should go to
CDC for medical check-ups**
< 0.001
Yes 752 (91.0) 22 (2.9) 1
No 74 (9.0) 14 (18.9) 7.7 3.8 - 15.9
Patient knows the duration of TB treatment 0.001
Yes 518 (61.6) 19 (3.7) 1
No 323 (38.4) 30 (9.3) 2.7 1.5 - 4.9
Patient agrees with the need for treatment observation** 0.06
Yes 209 (25.3) 4 (1.9) 1
No 616 (74.7) 31 (5.0) 2.7 0.95 - 7.8
Family attitude** 0.07
More supportive than usual 339 (40.3) 9 (2.7) 1
No change or less supportive than usual 502 (59.7) 40 (8.0) 2.1 0.95 - 4.5
RR = Relative Risk, 95%CI = 95% confidence interval.
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workload of village doctors, family members could pro-
vide DOT in China. A prerequisite is that they are
trained well, and remain motivated and committed to
the program.
Our study results support the results of previous
reports that stated that delayed care seeking (RR = 2.7)
and a high bacillary load at diagnosis (which may result
from delayed care seeking) also increase the risk of non-
cure [4,16,24-27]. Public awareness of presence of TB
dispensaries and the availability of free TB diagnosis and
treatment is low in China. In a recent survey 42% of the
interviewees were aware of the existence of TB dispen-
saries and 45% knew about the free diagnosis and treat-
ment policy for TB [28].
Patients without medical ins u r a n c em o r ef r e q u e n t l y
were not cured. In China, sputum smear examinations,
chest radiographs and anti-TB drugs are provided free
of charge, but additional costs, e.g. treatment of side-
effects are not [29,30]. Medical insurance covers part or
all of these extra costs. The financial burden for those
with no or partial insurance has been described to affect
treatment adherence [10,31]. The financial burden is
highest for those with a lower income. The 26 counties
w i t hac u r er a t eb e l o w8 5 %h a dal o w e ra v e r a g eg r o s s
domestic product per capita than the other counties in
Yunnan province (11,980 versus 13,826 RMB). Also the
number of health care workers per capita was lower
(218 versus 244 per 100,000 inhabitants). These factors
both may be an explanation for a lower overall cure
rate.
Our study has a number of limitations. We included
counties with a cure rate below 85% in 2005 in our
study. During the study period in 2007, the average cure
rate in these counties had increased to 94%. The lower
number of non-cured patients limited the statistical
power to detect determinants of unsuccessful treatment.
Furthermore, a lower successful treatment outcome per-
centage was observed among non-participants than
among participants (15% vs. 6%). Because the number of
non-participants with unsuccessful treatment outcome
was relatively small, we do not expect that non-partici-
pation in this study will have biased our findings to a
relevant extent.
Conclusions
Our study has provided us with useful insights on fac-
tors influencing non-cure in Yunnan province. Based on
the results, we recommend that patient education by
clinic doctors should be enhanced to improve the
patients’ understanding of their disease and its treatment
and to improve compliance with treatment and follow
up. More resources and effort are needed to educate the
general public to enable them to act effectively as com-
munity-based treatment observers.
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